- Incidence 25 per 100,000
Aetiology
- Single parathyroid adenoma (90%)
- Multiple adenomas or parathyroid hyperplasia (10%)
- Parathyroid carcinoma (1 - 2%)
- May form part of a syndrome such as MEN1, MEN2A or Familial isolated hyperparathyroidism
Pathophysiology
- Renal
- Increased calcium resorption in the loop of Henle, DCT and collecting duct
- Increased phosphate excretion in the PCT
- Increased production of vitamin D3 (1,25-dihydroxycholecalciferol)
- Gastrointestinal
- Increased indirect calcium reabsorption
- Bone
- Increased osteoclast activity and calcium release
- Inhibition of osteoblast activity
→ The net effect is hypercalcaemia and hypophosphataemia
Clinical features
Bones | Moans i.e. neuropsychiatric | Stones i.e. renal | Groans i.e. GI | Cardiovascular |
Bone pain | Depression (40%)/anxiety | Renal stones | Constipation | Hypertension |
Muscle weakness | Cognitive dysfunction | Polyuria | Anorexia | Tachycardia |
Fatigue | Confusion or psychosis | Dehydration | Nausea and vomiting | Short QTc |
Hyporeflexia | Insomnia | Pancreatitis (acute/chronic) | ST segment changes |
Investigations
- U&E may demonstrate:
- Raised calcium
- Raised chloride
- Low phosphate
- Impaired renal function
- Raised PTH
- Raised ALP from bony turnover
- Raised urinary calcium (or cAMP)
- The imaging modality of choice is technetium-99m-sesatmibi scintigraphy; a nuclear medicine scan which will identify the hyper-functioning gland
- It can facilitate minimally-invasive parathyroidectomy
Medical management
- Rehydration; may require several litres of crystalloid to replace deficit and dilute calcium
- Decrease skeletal release of calcium
- Bisphosphonates e.g. pamidronate 60mg/500ml 0.9% NaCl over 4hrs
- Calcitonin 3 - 4U/kg IV, followed by 4U/kg SC BD
- Other methods for reducing calcium
- Phosphate 500ml of 0.1M solution over 6 - 8hrs
- Furosemide diuresis e.g. 40mg IV every 4hrs
- Haemodialysis